Literature DB >> 26426315

Gastric emptying and disease activity in inflammatory bowel disease.

Jutta Keller1, Ulrich Binnewies1, Marie Rösch1, Jens Juul Holst2, Christoph Beglinger3, Viola Andresen1, Peter Layer1.   

Abstract

BACKGROUND: Gastric emptying (GE) is delayed in a subset of patients with inflammatory bowel disease (IBD). We have shown before that altered release of gastrointestinal hormones may contribute to GE disturbances, but overall effects of disease activity remain unclear. Thus, we aimed to evaluate GE in patients with IBD during active disease and following therapy.
DESIGN: A total of 20 healthy subjects (HC) and 26 patients with IBD hospitalized because of an acute episode of their disease (Crohn's disease (CD) n = 13, ulcerative colitis (UC) n = 13) underwent a standardized (13) C-octanoic acid GE breath test (baseline test). Plasma glucose, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) were measured periodically throughout the test. A total of 16 patients underwent a second GE test after 3-4 months of therapy.
RESULTS: At baseline, nine patients with IBD had pathologically delayed GE half-time (T½ > 150 min) (P = 0·028 vs. HC). Moreover, T½ was significantly longer in the total group of patients with IBD than in HC (129 ± 12 min vs. 96 ± 7, P = 0·030). Postprandial GLP-1 responses were elevated in IBD (P = 0·002 vs. HC) and correlated with T½ (P = 0·05). Following therapy clinical activity indices and T½ were decreased in IBD (P ≤ 0·01 vs. baseline), and T½ no longer differed from HC (P > 0·5). Moreover, GLP-1 plasma levels decreased significantly (P = 0·031).
CONCLUSIONS: Higher disease activity in IBD is associated with prolonged GE and increased release of GLP-1. Following effective therapy, GE is accelerated and GLP-1 release decreases significantly. Thus, increased release of GLP-1 from the inflamed mucosa might contribute to GE disturbances in IBD.
© 2015 Stichting European Society for Clinical Investigation Journal Foundation.

Entities:  

Keywords:  Disease activity; gastric emptying; hormonal regulation; hyperglycaemia; inflammatory bowel disease; motility

Mesh:

Substances:

Year:  2015        PMID: 26426315     DOI: 10.1111/eci.12542

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  17 in total

Review 1.  Gastrointestinal Complications of Obesity.

Authors:  Michael Camilleri; Harmeet Malhi; Andres Acosta
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

Review 2.  Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives.

Authors:  Hubert Zatorski; Maciej Sałaga; Jakub Fichna
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-07-29       Impact factor: 3.000

Review 3.  Enteroendocrine cells-sensory sentinels of the intestinal environment and orchestrators of mucosal immunity.

Authors:  J J Worthington; F Reimann; F M Gribble
Journal:  Mucosal Immunol       Date:  2017-08-30       Impact factor: 7.313

Review 4.  Abnormal gut motility in inflammatory bowel disease: an update.

Authors:  G Bassotti; E Antonelli; V Villanacci; R Nascimbeni; M P Dore; G M Pes; G Maconi
Journal:  Tech Coloproctol       Date:  2020-02-15       Impact factor: 3.781

5.  L-Glutamine and Physical Exercise Prevent Intestinal Inflammation and Oxidative Stress Without Improving Gastric Dysmotility in Rats with Ulcerative Colitis.

Authors:  Raisa de Oliveira Santos; Geovane da Silva Cardoso; Lara da Costa Lima; Mickael Laudrup de Sousa Cavalcante; Mariana Sousa Silva; Ana Karolina Martins Cavalcante; Juliana Soares Severo; Francisca Beatriz de Melo Sousa; Gabriella Pacheco; Even Herlany Pereira Alves; Lívia Maria Soares Nobre; Jand Venes Rolim Medeiros; Roberto Cesar Lima-Junior; Armênio Aguiar Dos Santos; Moisés Tolentino
Journal:  Inflammation       Date:  2020-10-31       Impact factor: 4.092

Review 6.  Role of Incretin Axis in Inflammatory Bowel Disease.

Authors:  Lihua Duan; Xiaoquan Rao; Zachary Braunstein; Amelia C Toomey; Jixin Zhong
Journal:  Front Immunol       Date:  2017-12-06       Impact factor: 7.561

7.  Gastric emptying after artificial ulceration in rats: differences due to the site of the ulcer and the effects of prokinetic drugs.

Authors:  Masayuki Uchida; Orie Kobayashi; Kimiko Shimizu
Journal:  J Smooth Muscle Res       Date:  2017

8.  Glucagon-like peptide 1 receptor (GLP-1R) expression by nerve fibres in inflammatory bowel disease and functional effects in cultured neurons.

Authors:  Uma Anand; Yiangos Yiangou; Ayesha Akbar; Tom Quick; Anthony MacQuillan; Mike Fox; Marco Sinisi; Yuri E Korchev; Ben Jones; Steve R Bloom; Praveen Anand
Journal:  PLoS One       Date:  2018-05-29       Impact factor: 3.240

Review 9.  European guideline on indications, performance and clinical impact of 13 C-breath tests in adult and pediatric patients: An EAGEN, ESNM, and ESPGHAN consensus, supported by EPC.

Authors:  Jutta Keller; Heinz F Hammer; Paul R Afolabi; Marc Benninga; Osvaldo Borrelli; Enrique Dominguez-Munoz; Dan Dumitrascu; Oliver Goetze; Stephan L Haas; Bruno Hauser; Daniel Pohl; Silvia Salvatore; Marc Sonyi; Nikhil Thapar; Kristin Verbeke; Mark R Fox
Journal:  United European Gastroenterol J       Date:  2021-06-14       Impact factor: 4.623

Review 10.  Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.

Authors:  Tamara Zietek; Eva Rath
Journal:  Front Immunol       Date:  2016-04-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.